NCT00206427 2021-09-29
GW
Baylor Breast Care Center
Phase 2 Completed
Clinical Trials
12 trialsNCT00263588 2019-12-12
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
Novartis
Phase 2 Completed
NCT02294786 2019-07-15
Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer
Novartis
Phase 2 Terminated
NCT00107003 2018-07-05
GW572016 to Treat Recurrent Malignant Brain Tumors
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01013740 2017-05-31
VITAL
Novartis
Phase 2 Completed
NCT00526669 2016-01-29
Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib
GlaxoSmithKline
Phase 2 Completed
NCT01985893 2016-01-14
THOR
Berufsverband Niedergelassener GynÀkologischer Onkologen in Deutschland e.V.
Phase 2 Withdrawn
NCT00430781 2015-05-08
Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer
GlaxoSmithKline
Phase 2 Completed
NCT01700010 2013-01-17
Trial of Lapatinib and Weekly Paclitaxel for Advanced Urothelial Cancer
University of Michigan Rogel Cancer Center
Phase 2 Withdrawn
NCT01128543 2012-12-12
Lapatinib in Combination With Vinorelbine
GlaxoSmithKline
Phase 2 Completed
NCT00447226 2012-06-12
Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists
GlaxoSmithKline
Phase 2 Terminated
NCT00888810 2009-04-28
TOPO-LAPA
Centre Francois Baclesse
Phase 2 Terminated